Literature DB >> 20168317

How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Steven M Paul1, Daniel S Mytelka, Christopher T Dunwiddie, Charles C Persinger, Bernard H Munos, Stacy R Lindborg, Aaron L Schacht.   

Abstract

The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs. However, it is widely acknowledged that trends in industry R&D productivity have been moving in the opposite direction for a number of years. Here, we present a detailed analysis based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity. We then propose specific strategies that could have the most substantial impact in improving R&D productivity.

Entities:  

Mesh:

Year:  2010        PMID: 20168317     DOI: 10.1038/nrd3078

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  25 in total

1.  Significance of the human genome sequence to drug discovery.

Authors:  O Grenet
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

2.  The value of improving the productivity of the drug development process: faster times and better decisions.

Authors:  Joseph A DiMasi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.

Authors:  Frank R Lichtenberg
Journal:  Int J Health Care Finance Econ       Date:  2005-03

Review 4.  Macro trends in pharmaceutical innovation.

Authors:  Fredric J Cohen
Journal:  Nat Rev Drug Discov       Date:  2005-01       Impact factor: 84.694

Review 5.  The prospects for "personalized medicine" in drug development and drug therapy.

Authors:  J Woodcock
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

6.  Drug discovery in jeopardy.

Authors:  Pedro Cuatrecasas
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

7.  Prescription drug spending trends in the United States: looking beyond the turning point.

Authors:  Murray Aitken; Ernst R Berndt; David M Cutler
Journal:  Health Aff (Millwood)       Date:  2008-12-16       Impact factor: 6.301

8.  Rebuilding the R&D engine in big pharma.

Authors:  Jean-Pierre Garnier
Journal:  Harv Bus Rev       Date:  2008-05

9.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

Review 10.  The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.

Authors:  Jeffrey A Kramer; John E Sagartz; Dale L Morris
Journal:  Nat Rev Drug Discov       Date:  2007-08       Impact factor: 84.694

View more
  735 in total

1.  Drug Discovery in Academia- the third way?

Authors:  Julie Frearson; Paul Wyatt
Journal:  Expert Opin Drug Discov       Date:  2010-10-01       Impact factor: 6.098

2.  Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics.

Authors:  K A Perkins; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

3.  Expanding precompetitive space.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2011-12       Impact factor: 84.694

4.  Can we really do computer-aided drug design?

Authors:  Matthew Segall
Journal:  J Comput Aided Mol Des       Date:  2011-12-11       Impact factor: 3.686

5.  New era for novel CNS drug development.

Authors:  William Z Potter
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

6.  New medications for substance use disorders: challenges and opportunities.

Authors:  Nora D Volkow; Phil Skolnick
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

7.  Enhancing Virtual Screening Performance of Protein Kinases with Molecular Dynamics Simulations.

Authors:  Tavina L Offutt; Robert V Swift; Rommie E Amaro
Journal:  J Chem Inf Model       Date:  2016-10-03       Impact factor: 4.956

8.  Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.

Authors:  Su Mi Choi; Yonghak Kim; Joong Sup Shim; Joon Tae Park; Rui-Hong Wang; Steven D Leach; Jun O Liu; Chuxia Deng; Zhaohui Ye; Yoon-Young Jang
Journal:  Hepatology       Date:  2013-06       Impact factor: 17.425

9.  Mass spectrometry imaging in zebrafish larvae for assessing drug safety and metabolism.

Authors:  Mariana Asslan; Nidia Lauzon; Maja Beus; Dusica Maysinger; Simon Rousseau
Journal:  Anal Bioanal Chem       Date:  2021-06-26       Impact factor: 4.142

10.  Screening reactive metabolites bioactivated by multiple enzyme pathways using a multiplexed microfluidic system.

Authors:  Dhanuka P Wasalathanthri; Ronaldo C Faria; Spundana Malla; Amit A Joshi; John B Schenkman; James F Rusling
Journal:  Analyst       Date:  2012-10-25       Impact factor: 4.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.